MHRA Plans a 14-Day First Review for Phase 1 Trials

MHRA published its Annual Report and Accounts for 2025-26 on 4 August 2026, laying before Parliament a year in which the agency says it met every statutory performance target it tracks. The report is, on its face, a scorecard. The operationally relevant line for trial sponsors sits further in: MHRA's own account of what 2026-27 brings, including a 14-day first assessment for Phase 1 clinical trials under new Clinical Trials Regulations the agency expects to implement this year.

The scorecard MHRA is choosing to tell

The headline figures are approval throughput and enforcement reach. MHRA approved 921 medicinal products across the year, 39 of them new medicines, and reports meeting 100% of its target timelines for both clinical trial applications and national medicines licence applications — a claim of full statutory compliance rather than a partial or averaged one. On enforcement, the agency removed close to 28 million doses of illegally traded medicines from circulation, with an estimated street value of £64.4 million, including the closure of what it describes as the UK's first known illegal factory producing unlicensed weight-loss injections. The report also notes MHRA's designation during the year as a World Health Organization Listed Authority, a status that signals to other regulators and to industry that the UK system meets WHO's benchmark for regulatory maturity — relevant to any sponsor relying on UK approval as part of a reliance pathway elsewhere.

The number that changes a submission timeline

Buried in the forward-looking section is the detail with the most immediate operational bite: MHRA says that in 2026-27 it will implement new Clinical Trials Regulations that include a 14-day first assessment for Phase 1 clinical trial applications. That is a first-assessment clock, not a full authorization guarantee, but it is a substantial compression of the front end of UK trial start-up for early-phase sponsors specifically — the population most sensitive to how fast a first cycle of regulatory feedback arrives. The report frames the change as part of a broader effort to make it easier and faster to run safe, high-quality clinical trials in the UK, alongside continued participation in the ACCESS consortium of international regulators on parallel scientific advice and assessment work.

What is still to come

MHRA has not yet published the Clinical Trials Regulations that would make the 14-day Phase 1 commitment binding, nor the MHRA2030 strategy the annual report says will arrive this year to set out how UK regulation should evolve on patient safety, NHS priorities, scientific innovation, and life-sciences growth through the end of the decade. Both are commitments stated in an annual report rather than instruments in force, and the specific mechanics of the 14-day clock — what triggers it, what a missed deadline means procedurally — are not detailed here. Sponsors planning Phase 1 submissions timed to land after the regulations take effect should treat the 14-day figure as a stated target to watch confirmed in the regulations themselves, not yet a rule they can submit against.